ArcticZymes Technologies ASA (DE:B4V) has released an update.
ArcticZymes Technologies ASA has initiated the AdEPT project, in collaboration with The Research Council of Norway, the University of Tromsø, and SINTEF Industri, with a funding of up to 11.8 MNOK to develop novel enzyme solutions for advanced therapy biomanufacturing. The project aims to tackle challenges in the production and analysis of therapeutic RNA, crucial for the cell and gene therapy sectors. CEO Michael B. Akoh expresses his commitment to enhancing the company’s enzyme portfolio and anticipates the project’s contribution to new therapeutic modalities.
For further insights into DE:B4V stock, check out TipRanks’ Stock Analysis page.
